Mondays play. CNB

Are you going to be holding through the possible r/s vote?

LOL. ya, I'm out even. Was fun while it lasted. This is my last post for the day. Was there any After Hours news today on anything.

Will talk to you later tonight or this weekend bud!

P.S. I feel a little queezy selling my FITB at 2.50 before I left to Korea........ sad panda face.

I fear the horns will poke me in the butt lol. 1 post left

$8.48

Look out BELOW LOW low loww....

ya I know, I was being sarcastic lol. You know mez.

LOL, TWICE EVEN! FITB has a lower high, pinched in the 5 min wedge, if it confirms should be a drop before market close.

I know that, I should have said the boards signaling a buy on prmo have also neglected to mention the vote of a R/S. I'm fine with my small loss. I've been in one R/S and care to never be in one again lol

Hey, i can only lose what I put in right?..................

BUT it's FITB. People gotta take profit sometime, why not now??? Because I said so.... lol NEARING 90 on the RSI toying with the 200MA Gapped up tons of profit for tons of people. Those tons of people gotta sell sometime!

$%%$@#, I need a smoke, this shorting buisness is kinda nervewrecking. brb

LOL. well, I might not LOLing in a few mins...

Doing my first short ever on FITB. STOP at a tad over HOD. Gotta learn sometime lol

OUT of OPMR. Don't want to be caught in another R/S. Took a small loss, not too bad. Seems the boards promoting OPMR are hiding the fact that they are voting on a R/S on the 23rd. I assume it's only a matter of time (this weekend) before the word travels through ihub and OPMR dumps on monday.

Morning

CTIC had some news.
Cell Therapeutics's Turnaround Remains On Track M2    "Press Wire "
M2 PressWIRE - May 8, 2009 - LOS ANGELES -- BiomedReports, the news portal covering the biomedical news and financial sector is profiling Cell Therapeutics (NASDAQ:CTIC) in a special report today.

The dramatic turnaround from lows of a nickel per share ealier this year at cancer biotech Cell Therapeutics (NASDAQ:CTIC) remains on track as the Company announced its 1Q09 results today, which included a 76% reduction of net loss and expected completion of the pixantrone NDA filing this June. Earlier this week, CTIC announced that pixantrone was made available through a compassionate use program in Europe on a named-patient basis for use in the treatment of aggressive non-Hodgkin's lymphoma (NHL) that has either relapsed or is refractory to standard treatment options.

CTIC achivied its objective thus far during 1H09, including the initiation of the rolling NDA submission for pixantrone, reducing net loss through cost cutting initiatives, raising gross proceeds of $44.3M , and cleaning up the Company's capital structure through the elimination of all previously issued preferred stock. CTIC is on target to complete the pixantrone NDA filing by June and if the FDA grants a priority revew, the Company could receive an approval decision before year-end in December.

A full special report by Mike Havrilla appears today at:

http://biomedreports.com/articles/most-popular/924-cell-therapeutics-turnaround-remains-on-track.html

About BiomedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to www.BiomedReports.com

Disclosure: No positions.

Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

((Comments on this story may be sent to info@m2.com))

© 2009 M2 COMMUNICATIONS LTD

nope :-/

NEXM up 39%+

NEXM closed AH over the 200MA at .33.

That 200ma is a key break IMO. will watch pre hours and odds are i'll jump in.

Look at NEXM. Massive volume, close right under 200ma, and a massive gap to fill. I can't find any news on it, not sure why it ran. If it breaks 200 again might be a good buy.

I, as a long, am still here and always will be. Until there is news, you will continue to see drama. We have had a lot of volume OUT OF NO WHERE. What does that mean? We shall see very soon IMO.

We have a HEAVY resistance at .0014 and .0015. No one wants to take that chance at a buying through those levels w/out news/facts. You have people/Nite playing games making sure that it does not break those resistances. In order to break them, we need a nice amount of confident buyers. How do we get confident buyers to break the resistance??? News! Nothing has changed here. We all know, most of us should know, what we are waiting for. There will be and always have been flippers from .0004-.0015. Who is it? I don't know and I don't care. I know why I INVESTED in this company, I know why i've been holding a VERY large amount of shares for over a year, and I konw I will be a very happy camper when my (longs) patience pays off.

So for those new investors who got in this week. Hold strong!

beautiful!

70x87

I agree, but when someone accusses the longs on no basis what-so-ever, the shit starts flying, as you see below this post lol.

There it is 5.11. lets see if we can do a 2 hour push to HOD.

More news yesterday. Pay attention to bold.

Moody's Downgrades Atlas Pipeline Partners' Debt to B3
Tuesday 05/05/2009 3:55 PM ET - Dow Jones News

Related Companies
Symbol Last %Chg
APL 5.07 -0.20%

As of 2:10 PM ET 5/6/09

By Christine Buurma
Of DOW JONES NEWSWIRES

NEW YORK (Dow Jones)--Moody's Investors Service said Tuesday that it has downgraded Atlas Pipeline Partners' (APL) corporate debt rating as the natural gas gatherer and processor struggles with tight liquidity and falling gas prices.
Moody's cut Atlas Pipeline Partners' corporate family rating and probability of default rating to B3 from B1, putting it deeper into speculative territory. Moon Township, Pa.-based Atlas' weak financial situation means the company will have to convince its lenders to ease the terms of their debt agreements, the ratings agency said.
Atlas has sold off several assets in an effort to pay down debt. On Monday, the company completed the sale of its NOARK natural gas gathering and transmission system to Spectra Energy Partners (SEP) for $300 Million. But the sale means less of Atlas' earnings will come fee-based pipelines, exposing the company to greater risk from volatile commodity prices, Moody's said.
"Moody's is concerned that Atlas' market position and tight liquidity makes it vulnerable to unanticipated events that could result in further declines in earnings and liquidity," Moody's said.
Tumbling gas prices and sliding gas demand have squeezed small pipeline operators like Atlas, while large companies like Spectra have been on the lookout for acquisitions.
Atlas Pipeline Partners' shares were recently up 59 cents, or 13.72%, at $4.89.

-By Christine Buurma, Dow Jones Newswires; 201-938-2061; christine.buurma@dowjones.com

Order free Annual Report for Atlas Energy Resources LLC
Visit http://djnewswires.ar.wilink.com/?link=ATN or call 1-888-301-0513
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http://www.djnewsplus.com/nae/al?rnd=W6UuMrXOzzpS27SyD3zXzg%3D%3D. You can use this link on the day this article is published and the following day.


(END) Dow Jones Newswires
05-05-09 1555ET
Copyright (c) 2009 Dow Jones & Company, Inc.

Lets break it!, 3rd times the charm!

glad i forgot about my sell order at .48 the other day lol....NICE!

nope, it flys

Can I get a ride someday? lol

BKUNA news, 3 potential buisnesses.

http://southflorida.bizjournals.com/southflorida/stories/2009/05/04/daily41.html?ana=yfcpc

If anyone thinks I/LONGS would waste our time flipping this every 3-5 months they are crazy.

I think you better watch yourself.

well if I ever meet nite in person I'm going to punch him in the teeth.

Lots of hits this morning, NICE! Gap closed

GAP almost closed heh

good morning friend

APL gapped to 5.25 from close of 5.08.